PMID- 31062358
OWN - NLM
STAT- MEDLINE
DCOM- 20200609
LR  - 20211204
IS  - 1097-4652 (Electronic)
IS  - 0021-9541 (Linking)
VI  - 234
IP  - 12
DP  - 2019 Dec
TI  - Assessment of the expression pattern of mTOR-associated lncRNAs and their genomic 
      variants in the patients with breast cancer.
PG  - 22044-22056
LID - 10.1002/jcp.28767 [doi]
AB  - The mechanistic target of rapamycin (mTOR) is a fundamental component of a 
      signaling pathway that is involved in the pathogenesis of breast cancer via 
      different mechanisms. This pathway is functionally linked with a number of small 
      nucleolar RNA host genes (SNHGs). In the present project, we have searched for 
      the expression quantitative trait loci (eQTLs) within SNHGs that are possibly 
      involved in the pathogenesis of breast cancer. Following this in silico step, we 
      have assessed expression levels of mTOR and four SNHGs in malignant and 
      nonmalignant samples obtained from 80 patients with breast cancer. We also 
      genotyped rs4615861 of SNHG3 and rs3087978 of SNHG5 in the peripheral blood of 
      patients. SNHG12 expression was not detected in any of the assessed malignant or 
      nonmalignant tissues. So this gene was excluded from further steps. Expression of 
      mTOR and other three long noncoding RNAs (lncRNAs) were significantly increased 
      in the malignant tissues compared with the nonmalignant tissues. When classifying 
      patients into down-/upregulation categorized based on the transcript levels of 
      each gene in malignant tissue versus nonmalignant tissues, we noticed 
      associations between expression of SNHG1 and stage (p = 0.03), expression of 
      SNHG5 and grade (p = 0.05), as well as between expression of SNHG3 and history of 
      oral contraceptive use (p = 0.04). We also detected higher levels of SNHG3 
      expression in estrogen receptor/progesterone receptor (ER/PR) negative tumors 
      compared with the ER/PR positive tumors (p  = 0.003 and p = 0.01, respectively). 
      Moreover, there was a trend toward higher expression of this lncRNA in 
      HER2-positive tumors compared with the HER2-negative ones (p = 0.07). Combination 
      of transcript levels of all genes could differentiate malignant tissues from 
      nonmalignant tissues with the diagnostic power of 69% (p = 0.0001). The rs3087978 
      was associated with the expression of mTOR in malignant tissues in a way that TT 
      and TG genotypes were associated with the higher and lower levels of expressions, 
      respectively (p = 0.01). The current study underscores the significance of SNHGs 
      in the pathogenesis of breast cancer.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Taherian-Esfahani, Zahra
AU  - Taherian-Esfahani Z
AD  - Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, 
      Tehran, Iran.
FAU - Taheri, Mohammad
AU  - Taheri M
AUID- ORCID: 0000-0001-8381-0591
AD  - Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Dashti, Sepideh
AU  - Dashti S
AD  - Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, 
      Tehran, Iran.
FAU - Kholghi-Oskooei, Vahid
AU  - Kholghi-Oskooei V
AD  - Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, 
      Tehran, Iran.
FAU - Geranpayeh, Lobat
AU  - Geranpayeh L
AD  - Department of Surgery, Sina Hospital, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Ghafouri-Fard, Soudeh
AU  - Ghafouri-Fard S
AUID- ORCID: 0000-0002-0223-499X
AD  - Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, 
      Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190506
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (long non-coding RNA SNHG5, human)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Breast Neoplasms/*genetics/pathology
MH  - Female
MH  - Genetic Variation
MH  - Genotype
MH  - Humans
MH  - Middle Aged
MH  - Quantitative Trait Loci
MH  - RNA, Long Noncoding/*genetics
MH  - TOR Serine-Threonine Kinases/*genetics
MH  - Transcriptome
OTO - NOTNLM
OT  - breast cancer
OT  - lncRNA
OT  - mTOR
EDAT- 2019/05/08 06:00
MHDA- 2020/06/10 06:00
CRDT- 2019/05/08 06:00
PHST- 2019/03/06 00:00 [received]
PHST- 2019/04/13 00:00 [revised]
PHST- 2019/04/17 00:00 [accepted]
PHST- 2019/05/08 06:00 [pubmed]
PHST- 2020/06/10 06:00 [medline]
PHST- 2019/05/08 06:00 [entrez]
AID - 10.1002/jcp.28767 [doi]
PST - ppublish
SO  - J Cell Physiol. 2019 Dec;234(12):22044-22056. doi: 10.1002/jcp.28767. Epub 2019 
      May 6.